TP53 and metastatic colorectal cancer: The more frequent presentation of co-altered Ras/Raf-TP53 tumors with extrahepatic metastasis, particularly to sites with limited opportunities for therapeutic salvage (e.g., peritoneal surface, bone, brain, etc.)may suggest a putative molecular basis for the clinical heterogeneity observed in metastatic colorectal cancer.